Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Akeso Biopharma, Inc. is currently navigating 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are split between 2 distinct examiners and 2 distinct art units. CUNNINGCHEN, KATHLEEN MARY is identified as the busiest examiner, accounting for 1 pending office action.
With 2 pending office actions spread across 2 distinct art units, the portfolio's active prosecution is not concentrated in 1 niche. Each of the 2 distinct examiners is handling exactly 1 pending office action. This distribution requires the applicant to manage 2 separate prosecution timelines and examiner styles. The presence of 2 distinct art units indicates that the underlying technology may be classified under different examination guidelines. Because the busiest examiner has only 1 pending action, the portfolio's immediate progress is not bottlenecked by 1 examiner's queue. The 2 pending office actions represent a diversified but small-scale prosecution effort.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CUNNINGCHEN, KATHLEEN MARY | 1 | 61.1% | +62.5% |
| SHUPE, ELIZABETH A | 1 | 66.2% | +44.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18264242 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHUPE, ELIZABETH A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18264138 | PHARMACEUTICAL COMPOSITION COMPRISING ANTI-TIGIT ANTIBODY AND ANTI-PD-1/ANTI-VEGFA BISPECIFIC ANTIBODY, AND USE THEREOF | CUNNINGCHEN, KATHLEEN MARY | — |
| 18264242 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHUPE, ELIZABETH A | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18264138 | PHARMACEUTICAL COMPOSITION COMPRISING ANTI-TIGIT ANTIBODY AND ANTI-PD-1/ANTI-VEGFA BISPECIFIC ANTIBODY, AND USE THEREOF | CUNNINGCHEN, KATHLEEN MARY | 1646 | §103DP | Non-Final OA | — | Pending | Aug 03, 2023 |
| 18264242 | PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHUPE, ELIZABETH A | 1643 | §103§112 | Non-Final OA | — | Pending | Aug 03, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial